larotrectinib,entrectinib
bayer,roche
['larotrectinib', 'sclc', 'entrectinib', 'nsclc']
#asco22 last abstract in this section is #9024 from dr. highlighting update on larotrectinib in #ntrk nsclc: rr 83%, mpfs and mos not reached. fairly comparable to entrectinib data. unique toxicities with ntrk inhibition important to remember. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him